secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K/A
Filed at:   2022-09-22T23:59:59+00:00
Accession:  0001628280-22-025322
Event type: other_material
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics board adopts annual advisory vote on exec compensation after stockholder recommendation
--------------------------------------------------------------------------------

- Stockholders voted in favor of a 1-year frequency for advisory votes on named executive officer compensation.
- Board determined to hold annual non-binding advisory votes until the next required frequency proposal.
- Amendment filed solely to disclose this frequency decision; original 8-K reported June 22, 2022 annual meeting results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828022025322/0001628280-22-025322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828022025322/cccc-20220622.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-025322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer